https://www.selleckchem.com/pr....oducts/sbc-115076.ht
Objective Whole-body MRI (WBMRI) is promising for monitoring patients' global disease activity in inflammatory joint diseases. The validation of WBMRI is limited; no studies have evaluated the test-retest agreement (interscan agreement) and only few have assessed the intra- and interreader agreement. Therefore we examined the interscan agreement of WBMRI in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA) and healthy controls (HC); and secondly evaluated the intraand interreader agreement and agreement with conventi
Like
Comment
Share
